or intra-arterial administration of therapeutic radionuclides or by direct implantation of radioisotope-embedded beads into tumors. [3] In external RT, therapeutic doses of ionizing radiation are delivered to tumors using external beams of photo ns, electrons, and protons. [4] Both types of RT can directly induce local apoptosis, autophagy, necrosis, or replicative senescence of cancer cells [5] by producing reactive oxygen species (ROS) [6] to cause DNA damage. [7] Advances in hardware and software technologies have provided conformal radiation techniques, [8] which are aided by advanced imaging systems to deliver a desired dose of radiation to the precise location of a tumor, thus maximizing therapeutic effects while minimizing radiation damage to normal organs. [9] Radiosensitizers can be introduced during RT to enhance the radiotherapeutic effects of ionizing radiation. The radiosensitizers can be classified as: 1) chemotherapies such as cisplatin, 5-fluorouracil, and taxanes; 2) gaseous molecules such as O 2 , NO, and H 2 S; and 3) high-Z elements such as Au, Ba, Bi, Pt, Hf, and W. Chemotherapies presumably enhance RT by arresting cancer cells in the most radiation-sensitive phases of the cell cycle and eliminating radioresistant cells in late S phase but often cause debilitating side effects to cancer patients. Gaseous radiosensitizers enhance RT by increasing ROS production and/or reducing the expression of hypoxia-inducible factor-1α (HIF-1α). It is, however, challenging to ensure therapeutic efficacy due to the difficulty in controlling their concentrations, diffusion rates, and tumor retention. High-Z elements enhance RT by increasing biological reactions and depositing more radiation energy in tumors, via their stronger interactions with secondary photons and electrons, than in normal tissues. [10] In addition to increasing local antitumor effects of RT, the holy grail of radiosensitizer design is to improve the killing of tumor cells outside of the irradiated fields (abscopal effect). An ideal radiosensitizer would enhance RT to produce systemic antitumor effects by inducing immunogenic cell death (ICD), enhancing the presentation of tumor-associated antigens (TAAs), and activating cytotoxic T cells to mount host immune responses.Although RT is widely used to treat many different types of tumors, it has several limitations. First, radio-resistance is a key impediment to both curative and palliative RT. Previous research on enhancing the effectiveness of RT has mainly focused on cancer cells while neglecting the complicated Radiotherapy (RT) uses ionizing radiation to eradicate localized tumors and, in rare cases, control tumors outside of the irradiated fields via stimulating an antitumor immune response (abscopal effect). However, the therapeutic effect of RT is often limited by inherent physiological barriers of the tumor microenvironment (TME), such as hypoxia, abnormal vasculature, dense extracellular matrix (ECM), and an immunosuppressive TME. Thus, it is critical to develop new RT strategies tha...